CompletedPhase 4

Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

Canada120 participantsStarted 2021-05-25

Plain-language summary

This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1 months. Participants will be randomized 1:1 to receive either a third dose of the mRNA-1273 vaccine or saline placebo at 3 months post initial vaccination.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Solid organ transplant recipient who has previously received Moderna vaccine at 0 and 1 months * Able to provide informed consent Exclusion Criteria: * Anaphylaxis or allergic reaction to Moderna vaccine

What they're measuring

anti-RBD antibody titer

Timeframe: 4-6 weeks after intervention

Trial details

NCT IDNCT04885907

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-07-30

View on ClinicalTrials.gov More Vaccine Response Impaired trials